If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-05. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
==== Cell selection ==== G418 is an aminoglycoside potent enough to kill mammalian cells. It is used in cell biology as a selective agent, killing off cells that have not taken up a resistance gene. When a genetic construct is inserted into a cell using a vector, biologists often use such a resistance gene as a selectable marker, allowing them to use a poison such as G418 to only keep the cells that have taken up the vector.
Engorgement is the swelling and stretching of the breast tissue due to the accumulation of fluid in the tissue surrounding and supporting the milk-producing cells and ducts. Engorgement most frequently occurs as milk "comes in" and during the weaning process. As milk is coming in, several processes occur. At the end of pregnancy, the blood vessels that supply the breast dilate, allowing for leaking into the tissue or interstitial space. Additionally, the birth of an infant is followed by massive fluid shifts to both offload excess fluid, which had been used to supply oxygen and nutrients to the fetus through the placenta, which is no longer needed, and supply additional fluid to the breasts to start the process of making milk. These fluid shifts often result in some of this excess fluid leaking into the breast tissue. Finally, milk "coming in" can create an uncomfortably full feeling, which, combined with the aforementioned fluid accumulation in the breast tissue, can cause severe pain. If breastfeeding is suddenly stopped, the breasts are likely to become engorged. Pumping small amounts to relieve discomfort helps to train the breasts to produce less milk gradually. There is presently no safe medication to prevent engorgement, but cold compresses and ibuprofen may help to relieve pain and swelling. Pain should go away with emptying of the breasts. If symptoms persist and comfort measures are not helpful, a blocked milk duct or infection may be present, and the affected person should seek medical intervention.
In 1957, Boyd Orr served as president of the Second International Humanist Congress, and contributed to the 1968 volume The Humanist Outlook alongside many other prominent humanists. In 1960 Boyd Orr was elected the first president of the World Academy of Art and Science, which was set up by eminent scientists of the day concerned about the potential misuse of scientific discoveries, most especially nuclear weapons. Along with Albert Einstein, Orr was one of the sponsors of the Peoples' World Convention (PWC), also known as Peoples' World Constituent Assembly (PWCA), which took place in 1950–51 at Palais Electoral, Geneva, Switzerland. He was also one of the signatories of the agreement to convene a convention for drafting a world constitution. As a result, for the first time in human history, a World Constituent Assembly convened to draft and adopt the Constitution for the Federation of Earth. Boyd Orr was a member of Bertrand Russell's Who Killed Kennedy? Committee which challenged the official version of the assassination of John F. Kennedy.
(See also: Bangladesh–United States relations#History) Later in 1974, India conducted its first nuclear test, Smiling Buddha, which was opposed by the US, however it also concluded that the test did not violate any agreement and proceeded with a June 1974 shipment of enriched uranium for the Tarapur reactor. In the late 1970s, with the Janata Party leader Morarji Desai becoming the prime minister, India improved its relations with the US, led by Jimmy Carter, despite the latter signing an order in 1978 barring nuclear material from being exported to India due to India's non-proliferation record. Despite the return of Indira Gandhi to power in 1980, the relations between the two countries continued to improve gradually, although India did not support the United States in its role in the Soviet invasion and occupation of Afghanistan. Indian Foreign Minister P. V. Narasimha Rao expressed "grave concern" over the United States's decision to "rearm" Pakistan; the two countries were working closely together to counter the Soviets in Afghanistan. The Reagan administration led by US President Ronald Reagan provided limited assistance to India. India sounded out Washington on the purchase of a range of US defence technology, including F-5 aircraft, super computers, night vision goggles and radars. In 1984, Washington approved the supply of selected technology to India including gas turbines for naval frigates and engines for prototypes for India's light combat aircraft.
Sources: en.wikipedia.org
=== Health care services === The disparity between those benefiting from treatment and those receiving it, known as the "treatment gap", arises from several factors. These include reluctance to seek treatment, healthcare providers' underdiagnosis, and limited availability and accessibility to advanced treatments. Furthermore, establishing clear pathways to services and medical care remains a challenge, complicating access to treatment for individuals with BPD. Despite efforts, many healthcare providers lack the training or resources to address severe BPD effectively, an issue acknowledged by both affected individuals and medical professionals. In the context of psychiatric hospitalizations, individuals with BPD constitute approximately 20% of admissions. While many engage in outpatient treatment consistently over several years, reliance on more restrictive and expensive treatment options, such as inpatient admission, tends to decrease over time. Service experiences vary among individuals with BPD. Assessing suicide risk poses a challenge for clinicians, with patients underestimating the lethality of self-harm behaviors. The suicide risk among people with BPD is significantly higher than that of the general population, characterized by a history of multiple suicide attempts during crises.
==== Astrocytes and blood oxygen levels ==== The Sur lab has discovered novel and critical roles for astrocytes in brain function. By high resolution imaging in the intact visual cortex, they showed that astrocytes have tuned calcium responses to visual stimuli that are mediated importantly via glutamate transporters on astrocyte processes that surround synapses, and they influence local blood flow and hence the hemodynamic signals that underlie brain imaging methods such as fMRI. Role of astrocytes in information processing and plasticity Astrocytes are also activated by neuromodulators such as acetylcholine and norepinephrine, and Sur and coworkers showed that cholinergic inputs to cortex act via astrocytes to alter the strength of excitatory synapses and implement plasticity of neuronal responses. Furthermore, astrocyte GABA transporters regulate extrasynaptic GABA and influence population coding of visual information by V1 neurons. Astrocyte calcium signaling influences excitatory drive to inhibitory neurons, thereby enabling astrocytes to modulate excitatory-inhibitory balance in neuronal V1 circuits. Astrocytes and learning Glutamate transporters on astrocytes regulate developmental plasticity in visual cortex. Gene expression (of glutamate and GABA transporters) in cortical astrocytes is modulated by learning, and astrocytes thus crucially shape cortical neuronal activity underlying learned behavior.
The skin supports its own ecosystems of microorganisms, including yeasts and bacteria, which cannot be removed by any amount of cleaning. Estimates place the number of individual bacteria on the surface of human skin at 7.8 million per square centimetre (50 million per square inch), though this figure varies greatly over the average 1.9 square metres (20 sq ft) of human skin. Oily surfaces, such as the face, may contain over 78 million bacteria per square centimetre (500 million per square inch). Despite these vast quantities, all of the bacteria found on the skin's surface would fit into a volume the size of a pea. In general, the microorganisms keep one another in check and are part of a healthy skin. When the balance is disturbed, there may be an overgrowth and infection, such as when antibiotics kill microbes, resulting in an overgrowth of yeast. The skin is continuous with the inner epithelial lining of the body at the orifices, each of which supports its own complement of microbes. Cosmetics should be used carefully on the skin because these may cause allergic reactions. Each season requires suitable clothing in order to facilitate the evaporation of the sweat. Sunlight, water and air play an important role in keeping the skin healthy.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.